Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: If each potential infringer has been given a ballpark figure for a license,

"how many would prefer to settle before re-examination is completed?"

According to the current lack of licensees several hundreds of informed companies don't seem to be afraid of the USPTO outcome .

From the Conference Call:

"The decline is attributable primarily to the previously stated reduction in MMP portfolio licensing activity."

I'd really wish, those companies would share my view, that the probability of a positive revalidation is higher than the rejection, but so far I see no signs for this.

Maybe the license prices have NOT gone up as we hoped, so it's still ok for many companies to wait for the USPTO decision?

GLTY

Share
New Message
Please login to post a reply